FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Vashington,	D.C.	20549

wasiiiigtoii,	D.C. 20349	

OMB APPROVAL OMB Number: Estimated average burden

0.5

hours per response:

Check this box if no longer subject t	C
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

							` '		cker or Trading			01 1040	5.5	Pelationel	in of P	Penortina	Dere	nn(s) to lee	ıer T			
1. Name and Address of Reporting Person* GROOPMAN JEROME				2. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ONTX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)										
GROOPMAN JEROME									-			_		-	ector	r		10% Ov				
(Last)	(Ei	rst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)									Off bel		ve title		Other (s below)	pecify			
C/O ONCONOVA THERAPEUTICS, INC.					07/26/2019									,			,					
			0, 1110.																			
375 PHEASANT RUN					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street)													- 1	,	m filed	l bv One I	Repo	rting Persor	,			
NEWTO	WN PA	1	18940										Form filed by More than One Reporting Person									
(City)	(SI	ate)	(Zip)																			
		Tab	le I - Non-l	Derivat	tive S	ecur	ities	s Ac	cquired, Di	ispo	sed o	f, or Ber	neficial	ly Owr	ed							
Date			2. Transact Date Month/Day	Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3, 4		4 and Securitie Beneficia		es For ally (D) Following (I) (Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership					
						Code V	А	Amount	nt (A) or P		Tran	rted saction : 3 and	tion(s)			(Instr. 4)						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code (Inst				ive ies ed	6. Date Exercisable Expiration Date (Month/Day/Year)		le and 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		f g Security	8. Price Derivat Securit (Instr. 5	ve de / Se) Be Or Fo Re Tr	Number erivative ecurities eneficially wned ollowing eported ransactionstr. 4)	is illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Cod	de V	(A)	,	(D)	Date Exercisable	Expi	oiration e	Title	Amount or Number of Shares									
Stock Option (right to purchase)	\$3.39	07/26/2019		А	A .	5,8	333		07/26/2020 ⁽¹⁾	07/2	26/2029	Common Stock	5,833	\$0		5,833		D				

Explanation of Responses:

1. These options vest 100% on the first anniversary of the grant date.

/s/ Mark Guerin as attorney-in-

fact

** Signature of Reporting Person

Date

07/29/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.